PRRT2 and hepatocellular carcinoma: A recent glycoproteomic study identified 113 LacdiNAc-modified glycopeptides from 33 glycoproteins, revealing that LacdiNAc-containing N-glycans are specifically upregulated in iCCA but not in hepatocellular carcinoma (HCC), underscoring their potential as iCCA-specific biomarkers and therapeutic targets (19).